Photo by Christina Victoria Craft on UnsplashThe following post was written and/or published as a collaboration between Benzinga’s in-house sponsored content team and a financial...
Investing.com – U.S. equities were mixed at the close on Monday, as gains in the Technology, Consumer Services and Consumer Goods sectors propelled shares higher while losses in...
By Sam BougheddaInvesting.com — Shares of biotechnology firm Jasper Therapeutics (NASDAQ:JSPR) soared 112% after Oppenheimer analyst Jay Olson initiated coverage of the company...
Base your stock investment decisions on fundamental values rather than short-term price activity.
A deep dive look at Amgen, its valuation, its future prospects, and the quality and strength of its financial statement.
Type | 5 Min | 15 Min | Hourly | Daily | Monthly |
|---|---|---|---|---|---|
| Moving Averages | |||||
| Technical Indicators | |||||
| Summary |
Name | Last | High | Low | Chg. | Chg. % | Vol. | Time | ||
|---|---|---|---|---|---|---|---|---|---|
| 0.18 | 0.00 | 0.00 | 0.0000 | 0.00% | 199.50K | TSXV | |||
| 0.23 | 0.00 | 0.00 | -0.01 | -6.25% | 31.61K | CSE | |||
| 1.28 | 1.35 | 1.22 | -0.120 | -8.57% | 57.74K | TSXV | |||
| 0.22 | 0.00 | 0.00 | 0.0000 | 0.00% | 323.00K | TSXV | |||
| 0.025 | 0.00 | 0.00 | 0.0000 | 0.00% | 295.64K | TSXV | |||
| 13.75 | 14.55 | 13.44 | -0.710 | -4.91% | 139.12K | NEO | |||
| 8.17 | 8.31 | 7.65 | -0.3800 | -4.44% | 131.74K | TSXV | |||
| 0.61 | 0.00 | 0.00 | +0.03 | +5.17% | 48.17K | TSXV | |||
| 35.59 | 35.81 | 35.22 | -0.13 | -0.36% | 2.66M | Toronto | |||
| 0.48 | 0.00 | 0.00 | -0.040 | -7.69% | 102.21K | TSXV | |||
| 0.045 | 0.00 | 0.00 | -0.0050 | -10.00% | 11.09K | TSXV | |||
| 0.17 | 0.00 | 0.00 | 0.0000 | 0.00% | 124.00K | TSXV | |||
| 21.77 | 21.83 | 21.68 | 0.00 | 0.00% | 0.00 | Toronto | |||
| 0.02 | 0.00 | 0.00 | 0.000 | 0.00% | 1.00K | CSE | |||
| 0.01 | 0.00 | 0.00 | -0.0050 | -33.33% | 384.18K | TSXV |
Amgen Inc. is a biotechnology company. The Company discovers, develops, manufactures and delivers various human therapeutics. It operates in human therapeutics segment. Its marketed products portfolio includes Neulasta (pegfilgrastim); erythropoiesis-stimulating agents (ESAs), such as Aranesp (darbepoetin alfa) and EPOGEN (epoetin alfa); Sensipar/Mimpara (cinacalcet); XGEVA (denosumab); Prolia (denosumab); NEUPOGEN (filgrastim), and other marketed products, such as KYPROLIS (carfilzomib), Vectibix (panitumumab), Nplate (romiplostim), Repatha (evolocumab), BLINCYTO (blinatumomab), IMLYGIC (talimogene laherparepvec) and Corlanor (ivabradine). It focuses on human therapeutics for the treatment of serious illness in the areas of oncology/hematology, cardiovascular disease and neuroscience. Its product candidates in Phase III include Erenumab for episodic migraine, Aranesp for myelodysplastic syndromes, BLINCYTO for acute lymphoblastic leukemia and IMLYGIC for metastatic melanoma.